Japan’s AMED Taps Genomics In Rare Disease Project
This article was originally published in PharmAsia News
Making good on plans outlined earlier this year, and mirroring similar initiatives elsewhere, Japan's new Agency for Medical R&D has kicked off a new project to use genome analysis to help identify and treat rare diseases, as part of its remit to encourage collaborative research and promote public health.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.